Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. De La Cruz
OA10.01 Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
Different Mutational Characteristics of the Subsets of EGFR-tyrosine Kinase Inhibitor Sensitizing Mutation-Positive Lung Adenocarcinoma
BMC Cancer
Cancer Research
Oncology
Genetics
PCN134 Patient Preferences for Non-Small Cell Lung Cancer (NSCLC) Treatments
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor
OncoTargets and Therapy
Oncology
Pharmacology
Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Impressive Response to Tyrosine Kinase Inhibitors in a Patient With Respiratory Failure for EGFR -Mutated Metastatic Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
PCC0208027, a Novel Tyrosine Kinase Inhibitor, Inhibits Tumor Growth of NSCLC by Targeting EGFR and HER2 Aberrations
Scientific Reports
Multidisciplinary
P3.01-75 RELAY+, an Exploratory Study of Gefitinib With Ramucirumab in Untreated Patients With EGFR Mutation-Positive Metastatic NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC
Lung Cancer Management
Association of Exon 19 and 21 EGFR Mutation Patterns With Treatment Outcome After First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary